Table 4.
Ongoing lenalidomide-based regime trials.
| Name | Phase | Age | Histology | Drugs | Status |
|---|---|---|---|---|---|
| NCT01419795 | II | >18 ys | Relapsed or refractory NHL after allo-SCT | RL | Ongoing and recruiting |
| NCT00238238 | II | >18 ys | Relapsed follicular NHL | RL | Ongoing and recruiting |
| NCT00633594 | I/II | >18 ys | Relapsed or refractory MCL | RVL | Ongoing and recruiting |
| NCT00553644 (27) | II | >18 ys | Relapsed or refractory MCL | LV | Ongoing and recruiting |
RL: rituximab, lenalidomide; RVL: rituximab, bortezomib, lenalidomide; LV: lenalidomide, bortezomib.